AKT1 and lung adenocarcinoma: Emerging evidence from lung adenocarcinoma studies (11) demonstrates that thrombin, the catalytic product of fibrinogen, can cleave epidermal growth factor receptor (EGFR) to activate AKT/mTOR signaling pathways, providing a direct molecular mechanism linking coagulation activation to chemotherapy resistance.